Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.